Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

Lundbeck may buy GSK drugs to complement portfolio: Sydbank

October 15, 2014
Life sciences
(Reuters) – Danish pharmaceutical group Lundbeck (LUN.CO) is one of the potential bidders for some of the older products worth in total $3 billion that British GlaxoSmithKline (GSK.L) is looking to divest, according to sources.
 
Lundbeck is reviewing a bid for products marketed in North America as it seeks to expand there, two sources told Reuters.
 
Shares in Lundbeck are traded 2.1 percent higher on Wednesday at 1045 GMT (0645 EDT) outperforming a 0.6 percent fall in the Danish benchmark index .OMXC20CAP.
 
Analysts made the following comments:
 
ANALYST SOREN LONTOFT HANSEN, SYDBANK
 
“Lundbeck could be looking at drugs that could complement its existing drug portfolio. We have seen that before, for example when the company bought Chelsea Therapeutics International, whose neurodrug Northera had just been approved in the United States.
 
“The patents expire on some of Lundbeck’s most significant products these years. The company has some of its own developed products as Selincro and Brintellix, and with the Japanese partner Otsuka it has Abilify Maintena. But it takes time to penetrate the market for these drugs, so I think Lundbeck is also looking for alternatives which can complement the existing pipeline, and where it makes sense for their salesmen also to have these drugs with them, when they visit customers”.
 
“Lundbeck has built a decent business in North America on drugs for some relatively rare diseases and they are still building on that what with Abilify Maintena and Brintellix”.
 
“There’s a giant potential on the U.S. market. It makes sense to use the existing sales force to take on a few more drugs. So it will probably be some drugs that complements some of Lundbeck’s existing drugs.”
 
(Reporting by Teis Jensen; editing by Sabina Zawadzki)

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach